nodes	percent_of_prediction	percent_of_DWPC	metapath
Tranexamic Acid—PLG—artery—systemic scleroderma	0.0504	0.23	CbGeAlD
Tranexamic Acid—PLG—endothelium—systemic scleroderma	0.0425	0.194	CbGeAlD
Tranexamic Acid—PLG—blood vessel—systemic scleroderma	0.0392	0.179	CbGeAlD
Tranexamic Acid—PLG—amb2 Integrin signaling—SELP—systemic scleroderma	0.0204	0.0774	CbGpPWpGaD
Tranexamic Acid—PLG—connective tissue—systemic scleroderma	0.0201	0.0917	CbGeAlD
Tranexamic Acid—PLG—smooth muscle tissue—systemic scleroderma	0.0184	0.0839	CbGeAlD
Tranexamic Acid—PLG—skin of body—systemic scleroderma	0.0182	0.0828	CbGeAlD
Tranexamic Acid—PLG—amb2 Integrin signaling—ITGAM—systemic scleroderma	0.0163	0.0619	CbGpPWpGaD
Tranexamic Acid—PLG—digestive system—systemic scleroderma	0.0145	0.0662	CbGeAlD
Tranexamic Acid—PLG—amb2 Integrin signaling—CTGF—systemic scleroderma	0.0136	0.0517	CbGpPWpGaD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—ITGAM—systemic scleroderma	0.0131	0.0498	CbGpPWpGaD
Tranexamic Acid—PLG—lung—systemic scleroderma	0.0121	0.0553	CbGeAlD
Tranexamic Acid—PLG—Regulation of IGF Activity by IGFBP—MMP1—systemic scleroderma	0.0115	0.0435	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—CSF1—systemic scleroderma	0.011	0.0419	CbGpPWpGaD
Tranexamic Acid—PLG—p75(NTR)-mediated signaling—RHOB—systemic scleroderma	0.0103	0.0391	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—SELP—systemic scleroderma	0.00982	0.0372	CbGpPWpGaD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.00935	0.0354	CbGpPWpGaD
Tranexamic Acid—PLG—Regulation of IGF Activity by IGFBP—MMP2—systemic scleroderma	0.00887	0.0336	CbGpPWpGaD
Tranexamic Acid—PLG—Activation of Matrix Metalloproteinases—MMP1—systemic scleroderma	0.00819	0.031	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—HSPG2—systemic scleroderma	0.00794	0.0301	CbGpPWpGaD
Tranexamic Acid—PLG—amb2 Integrin signaling—MMP2—systemic scleroderma	0.00633	0.024	CbGpPWpGaD
Tranexamic Acid—PLG—Activation of Matrix Metalloproteinases—MMP2—systemic scleroderma	0.00633	0.024	CbGpPWpGaD
Tranexamic Acid—PLG—amb2 Integrin signaling—MMP9—systemic scleroderma	0.00476	0.018	CbGpPWpGaD
Tranexamic Acid—PLG—Syndecan-4-mediated signaling events—MMP9—systemic scleroderma	0.00476	0.018	CbGpPWpGaD
Tranexamic Acid—PLG—Activation of Matrix Metalloproteinases—MMP9—systemic scleroderma	0.00476	0.018	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—FBN1—systemic scleroderma	0.00475	0.018	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.00459	0.0174	CbGpPWpGaD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.00443	0.0168	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.00435	0.0165	CbGpPWpGaD
Tranexamic Acid—PLG—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.00415	0.0157	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.00407	0.0154	CbGpPWpGaD
Tranexamic Acid—SLC15A2—lung—systemic scleroderma	0.00388	0.0177	CbGeAlD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—systemic scleroderma	0.00383	0.0145	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—CCL2—systemic scleroderma	0.00373	0.0141	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.0037	0.014	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—MMP1—systemic scleroderma	0.00361	0.0137	CbGpPWpGaD
Tranexamic Acid—PLG—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.00348	0.0132	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—COL1A2—systemic scleroderma	0.00333	0.0126	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—HSPG2—systemic scleroderma	0.00333	0.0126	CbGpPWpGaD
Tranexamic Acid—PLG—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—systemic scleroderma	0.00316	0.012	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—ITGAM—systemic scleroderma	0.00302	0.0114	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.00296	0.0112	CbGpPWpGaD
Tranexamic Acid—PLG—Folate Metabolism—IL1B—systemic scleroderma	0.00283	0.0107	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—MMP2—systemic scleroderma	0.00279	0.0106	CbGpPWpGaD
Tranexamic Acid—PLG—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.00225	0.00852	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—SELP—systemic scleroderma	0.00224	0.00851	CbGpPWpGaD
Tranexamic Acid—PLG—Degradation of the extracellular matrix—MMP9—systemic scleroderma	0.0021	0.00796	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—RHOB—systemic scleroderma	0.0021	0.00794	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—CSK—systemic scleroderma	0.00191	0.00723	CbGpPWpGaD
Tranexamic Acid—PLG—Platelet degranulation—TGFB1—systemic scleroderma	0.00189	0.00715	CbGpPWpGaD
Tranexamic Acid—PLG—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	0.0018	0.00681	CbGpPWpGaD
Tranexamic Acid—PLG—Hemostasis—ITGAM—systemic scleroderma	0.00179	0.0068	CbGpPWpGaD
Tranexamic Acid—PLG—Extracellular matrix organization—MMP1—systemic scleroderma	0.00151	0.00574	CbGpPWpGaD
Tranexamic Acid—Anaphylactic shock—Captopril—systemic scleroderma	0.00121	0.00233	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Mycophenolic acid—systemic scleroderma	0.0012	0.00233	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Azathioprine—systemic scleroderma	0.0012	0.00231	CcSEcCtD
Tranexamic Acid—Arrhythmia—Mycophenolic acid—systemic scleroderma	0.00119	0.00231	CcSEcCtD
Tranexamic Acid—Anaemia—Azathioprine—systemic scleroderma	0.00119	0.00231	CcSEcCtD
Tranexamic Acid—Pulmonary embolism—Methotrexate—systemic scleroderma	0.00119	0.0023	CcSEcCtD
Tranexamic Acid—Fatigue—Mometasone—systemic scleroderma	0.00118	0.00229	CcSEcCtD
Tranexamic Acid—Back pain—Leflunomide—systemic scleroderma	0.00118	0.00228	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00117	0.00227	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—MMP2—systemic scleroderma	0.00117	0.00444	CbGpPWpGaD
Tranexamic Acid—Muscle spasms—Leflunomide—systemic scleroderma	0.00117	0.00227	CcSEcCtD
Tranexamic Acid—Malaise—Azathioprine—systemic scleroderma	0.00116	0.00225	CcSEcCtD
Tranexamic Acid—Acute coronary syndrome—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00224	CcSEcCtD
Tranexamic Acid—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00223	CcSEcCtD
Tranexamic Acid—Myocardial infarction—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00222	CcSEcCtD
Tranexamic Acid—Asthenia—Pentoxifylline—systemic scleroderma	0.00114	0.00221	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Leflunomide—systemic scleroderma	0.00113	0.00219	CcSEcCtD
Tranexamic Acid—Hypotension—Captopril—systemic scleroderma	0.00113	0.00218	CcSEcCtD
Tranexamic Acid—Anaemia—Leflunomide—systemic scleroderma	0.00113	0.00218	CcSEcCtD
Tranexamic Acid—Back pain—Mycophenolic acid—systemic scleroderma	0.00112	0.00217	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00112	0.00217	CcSEcCtD
Tranexamic Acid—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.00112	0.00216	CcSEcCtD
Tranexamic Acid—Flushing—Lisinopril—systemic scleroderma	0.00112	0.00216	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—ACE—systemic scleroderma	0.0011	0.00418	CbGpPWpGaD
Tranexamic Acid—Sinusitis—Mycophenolate mofetil—systemic scleroderma	0.0011	0.00213	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.0011	0.00213	CcSEcCtD
Tranexamic Acid—Malaise—Leflunomide—systemic scleroderma	0.0011	0.00212	CcSEcCtD
Tranexamic Acid—Arthralgia—Azathioprine—systemic scleroderma	0.0011	0.00212	CcSEcCtD
Tranexamic Acid—Myalgia—Azathioprine—systemic scleroderma	0.0011	0.00212	CcSEcCtD
Tranexamic Acid—Angiopathy—Lisinopril—systemic scleroderma	0.00109	0.00211	CcSEcCtD
Tranexamic Acid—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00109	0.00211	CcSEcCtD
Tranexamic Acid—Abdominal pain—Mometasone—systemic scleroderma	0.00109	0.0021	CcSEcCtD
Tranexamic Acid—Discomfort—Azathioprine—systemic scleroderma	0.00108	0.0021	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Lisinopril—systemic scleroderma	0.00108	0.0021	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Mycophenolic acid—systemic scleroderma	0.00108	0.00209	CcSEcCtD
Tranexamic Acid—Dyspnoea—Captopril—systemic scleroderma	0.00108	0.00208	CcSEcCtD
Tranexamic Acid—Arrhythmia—Lisinopril—systemic scleroderma	0.00107	0.00208	CcSEcCtD
Tranexamic Acid—Anaemia—Mycophenolic acid—systemic scleroderma	0.00107	0.00208	CcSEcCtD
Tranexamic Acid—Dyspepsia—Captopril—systemic scleroderma	0.00106	0.00205	CcSEcCtD
Tranexamic Acid—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	0.00106	0.00205	CcSEcCtD
Tranexamic Acid—Pulmonary oedema—Methotrexate—systemic scleroderma	0.00106	0.00205	CcSEcCtD
Tranexamic Acid—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00204	CcSEcCtD
Tranexamic Acid—Dizziness—Pentoxifylline—systemic scleroderma	0.00105	0.00204	CcSEcCtD
Tranexamic Acid—Malaise—Mycophenolic acid—systemic scleroderma	0.00105	0.00203	CcSEcCtD
Tranexamic Acid—Fatigue—Captopril—systemic scleroderma	0.00104	0.00201	CcSEcCtD
Tranexamic Acid—Arthralgia—Leflunomide—systemic scleroderma	0.00104	0.00201	CcSEcCtD
Tranexamic Acid—Myalgia—Leflunomide—systemic scleroderma	0.00104	0.00201	CcSEcCtD
Tranexamic Acid—Chest pain—Leflunomide—systemic scleroderma	0.00104	0.00201	CcSEcCtD
Tranexamic Acid—Discomfort—Leflunomide—systemic scleroderma	0.00102	0.00198	CcSEcCtD
Tranexamic Acid—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.00102	0.00198	CcSEcCtD
Tranexamic Acid—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00196	CcSEcCtD
Tranexamic Acid—Back pain—Lisinopril—systemic scleroderma	0.00101	0.00196	CcSEcCtD
Tranexamic Acid—Vomiting—Pentoxifylline—systemic scleroderma	0.00101	0.00196	CcSEcCtD
Tranexamic Acid—Convulsion—Mycophenolic acid—systemic scleroderma	0.00101	0.00195	CcSEcCtD
Tranexamic Acid—Muscle spasms—Lisinopril—systemic scleroderma	0.00101	0.00195	CcSEcCtD
Tranexamic Acid—Headache—Pentoxifylline—systemic scleroderma	0.000997	0.00193	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000994	0.00192	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Captopril—systemic scleroderma	0.000994	0.00192	CcSEcCtD
Tranexamic Acid—Chest pain—Mycophenolic acid—systemic scleroderma	0.000989	0.00191	CcSEcCtD
Tranexamic Acid—Myalgia—Mycophenolic acid—systemic scleroderma	0.000989	0.00191	CcSEcCtD
Tranexamic Acid—Arthralgia—Mycophenolic acid—systemic scleroderma	0.000989	0.00191	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Captopril—systemic scleroderma	0.000986	0.00191	CcSEcCtD
Tranexamic Acid—Asthenia—Mometasone—systemic scleroderma	0.000985	0.00191	CcSEcCtD
Tranexamic Acid—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000984	0.0019	CcSEcCtD
Tranexamic Acid—Hypotension—Azathioprine—systemic scleroderma	0.000983	0.0019	CcSEcCtD
Tranexamic Acid—Polyuria—Methotrexate—systemic scleroderma	0.000982	0.0019	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000977	0.00189	CcSEcCtD
Tranexamic Acid—Discomfort—Mycophenolic acid—systemic scleroderma	0.000977	0.00189	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Leflunomide—systemic scleroderma	0.000975	0.00189	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Lisinopril—systemic scleroderma	0.000971	0.00188	CcSEcCtD
Tranexamic Acid—Anaemia—Lisinopril—systemic scleroderma	0.000967	0.00187	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000959	0.00186	CcSEcCtD
Tranexamic Acid—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000955	0.00185	CcSEcCtD
Tranexamic Acid—Abdominal pain—Captopril—systemic scleroderma	0.000953	0.00184	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000949	0.00184	CcSEcCtD
Tranexamic Acid—Nausea—Pentoxifylline—systemic scleroderma	0.000945	0.00183	CcSEcCtD
Tranexamic Acid—Malaise—Lisinopril—systemic scleroderma	0.000944	0.00183	CcSEcCtD
Tranexamic Acid—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000941	0.00182	CcSEcCtD
Tranexamic Acid—Diarrhoea—Mometasone—systemic scleroderma	0.000939	0.00182	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00093	0.0018	CcSEcCtD
Tranexamic Acid—Hypotension—Leflunomide—systemic scleroderma	0.000929	0.0018	CcSEcCtD
Tranexamic Acid—Loss of consciousness—Lisinopril—systemic scleroderma	0.00092	0.00178	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—SMAD7—systemic scleroderma	0.000918	0.00348	CbGpPWpGaD
Tranexamic Acid—Visual disturbance—Methotrexate—systemic scleroderma	0.00091	0.00176	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000909	0.00176	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000905	0.00175	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—MMP1—systemic scleroderma	0.000899	0.00341	CbGpPWpGaD
Tranexamic Acid—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.000891	0.00172	CcSEcCtD
Tranexamic Acid—Myalgia—Lisinopril—systemic scleroderma	0.000891	0.00172	CcSEcCtD
Tranexamic Acid—Chest pain—Lisinopril—systemic scleroderma	0.000891	0.00172	CcSEcCtD
Tranexamic Acid—Arthralgia—Lisinopril—systemic scleroderma	0.000891	0.00172	CcSEcCtD
Tranexamic Acid—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000887	0.00172	CcSEcCtD
Tranexamic Acid—Dyspnoea—Leflunomide—systemic scleroderma	0.000886	0.00171	CcSEcCtD
Tranexamic Acid—Hypotension—Mycophenolic acid—systemic scleroderma	0.000886	0.00171	CcSEcCtD
Tranexamic Acid—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000881	0.00171	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—MMP9—systemic scleroderma	0.00088	0.00334	CbGpPWpGaD
Tranexamic Acid—Discomfort—Lisinopril—systemic scleroderma	0.00088	0.0017	CcSEcCtD
Tranexamic Acid—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.00088	0.0017	CcSEcCtD
Tranexamic Acid—Dyspepsia—Leflunomide—systemic scleroderma	0.000875	0.00169	CcSEcCtD
Tranexamic Acid—Vomiting—Mometasone—systemic scleroderma	0.000873	0.00169	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Azathioprine—systemic scleroderma	0.000867	0.00168	CcSEcCtD
Tranexamic Acid—Asthenia—Captopril—systemic scleroderma	0.000865	0.00167	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000864	0.00167	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000861	0.00166	CcSEcCtD
Tranexamic Acid—Headache—Mometasone—systemic scleroderma	0.00086	0.00166	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000858	0.00166	CcSEcCtD
Tranexamic Acid—Fatigue—Leflunomide—systemic scleroderma	0.000857	0.00166	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000854	0.00165	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000851	0.00165	CcSEcCtD
Tranexamic Acid—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000847	0.00164	CcSEcCtD
Tranexamic Acid—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000845	0.00164	CcSEcCtD
Tranexamic Acid—PLG—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	0.000836	0.00317	CbGpPWpGaD
Tranexamic Acid—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000835	0.00161	CcSEcCtD
Tranexamic Acid—Abdominal pain—Azathioprine—systemic scleroderma	0.000832	0.00161	CcSEcCtD
Tranexamic Acid—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000827	0.0016	CcSEcCtD
Tranexamic Acid—Diarrhoea—Captopril—systemic scleroderma	0.000825	0.0016	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Leflunomide—systemic scleroderma	0.000819	0.00158	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000819	0.00158	CcSEcCtD
Tranexamic Acid—Fatigue—Mycophenolic acid—systemic scleroderma	0.000817	0.00158	CcSEcCtD
Tranexamic Acid—Nausea—Mometasone—systemic scleroderma	0.000815	0.00158	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000813	0.00157	CcSEcCtD
Tranexamic Acid—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000806	0.00156	CcSEcCtD
Tranexamic Acid—Hypotension—Lisinopril—systemic scleroderma	0.000798	0.00154	CcSEcCtD
Tranexamic Acid—Dizziness—Captopril—systemic scleroderma	0.000797	0.00154	CcSEcCtD
Tranexamic Acid—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000794	0.00154	CcSEcCtD
Tranexamic Acid—Abdominal pain—Leflunomide—systemic scleroderma	0.000786	0.00152	CcSEcCtD
Tranexamic Acid—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000784	0.00152	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000781	0.00151	CcSEcCtD
Tranexamic Acid—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00078	0.00151	CcSEcCtD
Tranexamic Acid—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00078	0.00151	CcSEcCtD
Tranexamic Acid—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00078	0.00151	CcSEcCtD
Tranexamic Acid—Myocardial infarction—Prednisone—systemic scleroderma	0.000779	0.00151	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000778	0.00151	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Azathioprine—systemic scleroderma	0.000775	0.0015	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000775	0.0015	CcSEcCtD
Tranexamic Acid—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000771	0.00149	CcSEcCtD
Tranexamic Acid—Vomiting—Captopril—systemic scleroderma	0.000767	0.00148	CcSEcCtD
Tranexamic Acid—Dyspnoea—Lisinopril—systemic scleroderma	0.000761	0.00147	CcSEcCtD
Tranexamic Acid—Headache—Captopril—systemic scleroderma	0.000755	0.00146	CcSEcCtD
Tranexamic Acid—Dyspepsia—Lisinopril—systemic scleroderma	0.000752	0.00145	CcSEcCtD
Tranexamic Acid—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000749	0.00145	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000748	0.00145	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000737	0.00143	CcSEcCtD
Tranexamic Acid—Fatigue—Lisinopril—systemic scleroderma	0.000736	0.00142	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000734	0.00142	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Leflunomide—systemic scleroderma	0.000732	0.00142	CcSEcCtD
Tranexamic Acid—PLG—Extracellular matrix organization—TGFB1—systemic scleroderma	0.000725	0.00275	CbGpPWpGaD
Tranexamic Acid—Diarrhoea—Azathioprine—systemic scleroderma	0.00072	0.00139	CcSEcCtD
Tranexamic Acid—Haemoglobin—Prednisone—systemic scleroderma	0.000717	0.00139	CcSEcCtD
Tranexamic Acid—Nausea—Captopril—systemic scleroderma	0.000716	0.00139	CcSEcCtD
Tranexamic Acid—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000715	0.00138	CcSEcCtD
Tranexamic Acid—Haemorrhage—Prednisone—systemic scleroderma	0.000714	0.00138	CcSEcCtD
Tranexamic Acid—Asthenia—Leflunomide—systemic scleroderma	0.000713	0.00138	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—RHOB—systemic scleroderma	0.00071	0.00269	CbGpPWpGaD
Tranexamic Acid—PLG—Metabolism of proteins—MMP1—systemic scleroderma	0.000707	0.00268	CbGpPWpGaD
Tranexamic Acid—Feeling abnormal—Lisinopril—systemic scleroderma	0.000704	0.00136	CcSEcCtD
Tranexamic Acid—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000699	0.00135	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000698	0.00135	CcSEcCtD
Tranexamic Acid—Dizziness—Azathioprine—systemic scleroderma	0.000696	0.00135	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000682	0.00132	CcSEcCtD
Tranexamic Acid—Asthenia—Mycophenolic acid—systemic scleroderma	0.00068	0.00132	CcSEcCtD
Tranexamic Acid—Diarrhoea—Leflunomide—systemic scleroderma	0.00068	0.00132	CcSEcCtD
Tranexamic Acid—Abdominal pain—Lisinopril—systemic scleroderma	0.000675	0.00131	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—HSPG2—systemic scleroderma	0.00067	0.00254	CbGpPWpGaD
Tranexamic Acid—Vomiting—Azathioprine—systemic scleroderma	0.000669	0.00129	CcSEcCtD
Tranexamic Acid—Eye disorder—Prednisone—systemic scleroderma	0.000667	0.00129	CcSEcCtD
Tranexamic Acid—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000667	0.00129	CcSEcCtD
Tranexamic Acid—Flushing—Prednisone—systemic scleroderma	0.000663	0.00128	CcSEcCtD
Tranexamic Acid—Headache—Azathioprine—systemic scleroderma	0.000659	0.00128	CcSEcCtD
Tranexamic Acid—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000659	0.00127	CcSEcCtD
Tranexamic Acid—Dizziness—Leflunomide—systemic scleroderma	0.000657	0.00127	CcSEcCtD
Tranexamic Acid—Renal failure—Methotrexate—systemic scleroderma	0.000653	0.00126	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—NOS3—systemic scleroderma	0.000652	0.00247	CbGpPWpGaD
Tranexamic Acid—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000649	0.00126	CcSEcCtD
Tranexamic Acid—Angiopathy—Prednisone—systemic scleroderma	0.000648	0.00125	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—CSK—systemic scleroderma	0.000647	0.00245	CbGpPWpGaD
Tranexamic Acid—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000646	0.00125	CcSEcCtD
Tranexamic Acid—Immune system disorder—Prednisone—systemic scleroderma	0.000645	0.00125	CcSEcCtD
Tranexamic Acid—Arrhythmia—Prednisone—systemic scleroderma	0.000638	0.00123	CcSEcCtD
Tranexamic Acid—Vomiting—Leflunomide—systemic scleroderma	0.000632	0.00122	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Lisinopril—systemic scleroderma	0.000629	0.00122	CcSEcCtD
Tranexamic Acid—Dizziness—Mycophenolic acid—systemic scleroderma	0.000627	0.00121	CcSEcCtD
Tranexamic Acid—Nausea—Azathioprine—systemic scleroderma	0.000625	0.00121	CcSEcCtD
Tranexamic Acid—Headache—Leflunomide—systemic scleroderma	0.000623	0.0012	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000617	0.00119	CcSEcCtD
Tranexamic Acid—Asthenia—Lisinopril—systemic scleroderma	0.000613	0.00119	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000612	0.00118	CcSEcCtD
Tranexamic Acid—Vomiting—Mycophenolic acid—systemic scleroderma	0.000603	0.00117	CcSEcCtD
Tranexamic Acid—Haemoglobin—Methotrexate—systemic scleroderma	0.0006	0.00116	CcSEcCtD
Tranexamic Acid—Haemorrhage—Methotrexate—systemic scleroderma	0.000597	0.00115	CcSEcCtD
Tranexamic Acid—Headache—Mycophenolic acid—systemic scleroderma	0.000594	0.00115	CcSEcCtD
Tranexamic Acid—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000591	0.00114	CcSEcCtD
Tranexamic Acid—Nausea—Leflunomide—systemic scleroderma	0.00059	0.00114	CcSEcCtD
Tranexamic Acid—Diarrhoea—Lisinopril—systemic scleroderma	0.000584	0.00113	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Prednisone—systemic scleroderma	0.000577	0.00112	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—CCL2—systemic scleroderma	0.000575	0.00218	CbGpPWpGaD
Tranexamic Acid—Visual impairment—Methotrexate—systemic scleroderma	0.000575	0.00111	CcSEcCtD
Tranexamic Acid—Anaemia—Prednisone—systemic scleroderma	0.000574	0.00111	CcSEcCtD
Tranexamic Acid—Dizziness—Lisinopril—systemic scleroderma	0.000565	0.00109	CcSEcCtD
Tranexamic Acid—Nausea—Mycophenolic acid—systemic scleroderma	0.000563	0.00109	CcSEcCtD
Tranexamic Acid—Malaise—Prednisone—systemic scleroderma	0.00056	0.00108	CcSEcCtD
Tranexamic Acid—Eye disorder—Methotrexate—systemic scleroderma	0.000558	0.00108	CcSEcCtD
Tranexamic Acid—Cardiac disorder—Methotrexate—systemic scleroderma	0.000554	0.00107	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000551	0.00107	CcSEcCtD
Tranexamic Acid—PLG—Metabolism of proteins—MMP2—systemic scleroderma	0.000547	0.00207	CbGpPWpGaD
Tranexamic Acid—Loss of consciousness—Prednisone—systemic scleroderma	0.000546	0.00106	CcSEcCtD
Tranexamic Acid—Vomiting—Lisinopril—systemic scleroderma	0.000543	0.00105	CcSEcCtD
Tranexamic Acid—Angiopathy—Methotrexate—systemic scleroderma	0.000541	0.00105	CcSEcCtD
Tranexamic Acid—Immune system disorder—Methotrexate—systemic scleroderma	0.000539	0.00104	CcSEcCtD
Tranexamic Acid—Convulsion—Prednisone—systemic scleroderma	0.000538	0.00104	CcSEcCtD
Tranexamic Acid—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000538	0.00104	CcSEcCtD
Tranexamic Acid—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000537	0.00104	CcSEcCtD
Tranexamic Acid—Headache—Lisinopril—systemic scleroderma	0.000535	0.00104	CcSEcCtD
Tranexamic Acid—Arthralgia—Prednisone—systemic scleroderma	0.000529	0.00102	CcSEcCtD
Tranexamic Acid—Myalgia—Prednisone—systemic scleroderma	0.000529	0.00102	CcSEcCtD
Tranexamic Acid—Discomfort—Prednisone—systemic scleroderma	0.000523	0.00101	CcSEcCtD
Tranexamic Acid—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000512	0.00099	CcSEcCtD
Tranexamic Acid—Nausea—Lisinopril—systemic scleroderma	0.000507	0.000981	CcSEcCtD
Tranexamic Acid—Anaphylactic shock—Prednisone—systemic scleroderma	0.000507	0.000981	CcSEcCtD
Tranexamic Acid—Back pain—Methotrexate—systemic scleroderma	0.000502	0.000972	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Prednisone—systemic scleroderma	0.000497	0.000962	CcSEcCtD
Tranexamic Acid—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000495	0.000957	CcSEcCtD
Tranexamic Acid—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000482	0.000932	CcSEcCtD
Tranexamic Acid—Anaemia—Methotrexate—systemic scleroderma	0.00048	0.000929	CcSEcCtD
Tranexamic Acid—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000476	0.00092	CcSEcCtD
Tranexamic Acid—Headache—Mycophenolate mofetil—systemic scleroderma	0.000469	0.000907	CcSEcCtD
Tranexamic Acid—Malaise—Methotrexate—systemic scleroderma	0.000468	0.000906	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000462	0.000894	CcSEcCtD
Tranexamic Acid—Convulsion—Methotrexate—systemic scleroderma	0.00045	0.000871	CcSEcCtD
Tranexamic Acid—Dyspepsia—Prednisone—systemic scleroderma	0.000446	0.000864	CcSEcCtD
Tranexamic Acid—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000444	0.00086	CcSEcCtD
Tranexamic Acid—Myalgia—Methotrexate—systemic scleroderma	0.000442	0.000855	CcSEcCtD
Tranexamic Acid—Arthralgia—Methotrexate—systemic scleroderma	0.000442	0.000855	CcSEcCtD
Tranexamic Acid—Chest pain—Methotrexate—systemic scleroderma	0.000442	0.000855	CcSEcCtD
Tranexamic Acid—Fatigue—Prednisone—systemic scleroderma	0.000437	0.000846	CcSEcCtD
Tranexamic Acid—Discomfort—Methotrexate—systemic scleroderma	0.000437	0.000845	CcSEcCtD
Tranexamic Acid—PLG—Hemostasis—TGFB1—systemic scleroderma	0.000431	0.00163	CbGpPWpGaD
Tranexamic Acid—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000424	0.00082	CcSEcCtD
Tranexamic Acid—Feeling abnormal—Prednisone—systemic scleroderma	0.000418	0.000809	CcSEcCtD
Tranexamic Acid—Nervous system disorder—Methotrexate—systemic scleroderma	0.000416	0.000804	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000415	0.000802	CcSEcCtD
Tranexamic Acid—Abdominal pain—Prednisone—systemic scleroderma	0.000401	0.000776	CcSEcCtD
Tranexamic Acid—Hypotension—Methotrexate—systemic scleroderma	0.000396	0.000766	CcSEcCtD
Tranexamic Acid—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000386	0.000747	CcSEcCtD
Tranexamic Acid—Dyspnoea—Methotrexate—systemic scleroderma	0.000378	0.000731	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Prednisone—systemic scleroderma	0.000374	0.000723	CcSEcCtD
Tranexamic Acid—Dyspepsia—Methotrexate—systemic scleroderma	0.000373	0.000722	CcSEcCtD
Tranexamic Acid—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000366	0.000708	CcSEcCtD
Tranexamic Acid—Fatigue—Methotrexate—systemic scleroderma	0.000365	0.000707	CcSEcCtD
Tranexamic Acid—Asthenia—Prednisone—systemic scleroderma	0.000364	0.000704	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—EDN1—systemic scleroderma	0.000363	0.00137	CbGpPWpGaD
Tranexamic Acid—Feeling abnormal—Methotrexate—systemic scleroderma	0.000349	0.000676	CcSEcCtD
Tranexamic Acid—Diarrhoea—Prednisone—systemic scleroderma	0.000347	0.000671	CcSEcCtD
Tranexamic Acid—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000347	0.000671	CcSEcCtD
Tranexamic Acid—Dizziness—Prednisone—systemic scleroderma	0.000335	0.000649	CcSEcCtD
Tranexamic Acid—Abdominal pain—Methotrexate—systemic scleroderma	0.000335	0.000648	CcSEcCtD
Tranexamic Acid—Vomiting—Prednisone—systemic scleroderma	0.000322	0.000624	CcSEcCtD
Tranexamic Acid—Headache—Prednisone—systemic scleroderma	0.000318	0.000615	CcSEcCtD
Tranexamic Acid—Hypersensitivity—Methotrexate—systemic scleroderma	0.000312	0.000604	CcSEcCtD
Tranexamic Acid—Asthenia—Methotrexate—systemic scleroderma	0.000304	0.000588	CcSEcCtD
Tranexamic Acid—Nausea—Prednisone—systemic scleroderma	0.000301	0.000583	CcSEcCtD
Tranexamic Acid—Diarrhoea—Methotrexate—systemic scleroderma	0.00029	0.000561	CcSEcCtD
Tranexamic Acid—Dizziness—Methotrexate—systemic scleroderma	0.00028	0.000542	CcSEcCtD
Tranexamic Acid—Vomiting—Methotrexate—systemic scleroderma	0.000269	0.000521	CcSEcCtD
Tranexamic Acid—Headache—Methotrexate—systemic scleroderma	0.000266	0.000514	CcSEcCtD
Tranexamic Acid—Nausea—Methotrexate—systemic scleroderma	0.000252	0.000487	CcSEcCtD
Tranexamic Acid—PLG—Signaling Pathways—CCL2—systemic scleroderma	0.000248	0.00094	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—NOS3—systemic scleroderma	0.000221	0.000838	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—MMP9—systemic scleroderma	0.000177	0.000672	CbGpPWpGaD
Tranexamic Acid—PLG—Signaling Pathways—TGFB1—systemic scleroderma	0.000146	0.000554	CbGpPWpGaD
